Bronchogen is a synthetic short-chain peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson — part of the broader "Khavinson bioregulators" family that includes Epitalon, Pinealon, Cortagen, and others. The Khavinson peptides share a common discovery framework (tissue-specific peptide extraction, sequence identification, synthetic re-creation) and a theoretical model in which short peptides modulate tissue-specific gene expression. This monograph lays out Bronchogen's chemical identity, the Khavinson framework as it applies to lung tissue, the published research record, and the considerations for evaluating a vendor-grade product.
Chemical identity and structure.
Bronchogen is a tetrapeptide with the sequence Ala-Asp-Glu-Leu (alanine-aspartic acid-glutamic acid-leucine). The molecule has been published in peer-reviewed Russian and international literature, including a 2011 paper in Bulletin of Experimental Biology and Medicine describing its effect on DNA thermostability. The peptide was identified from lung tissue extracts using the Khavinson bioregulator-discovery protocol and is supplied as a lyophilized white-to-off-white powder, water-soluble, and stable under standard short-peptide storage conditions.
Mechanism of action.
The Khavinson framework hypothesises that short peptides cross cell membranes, reach nuclear chromatin, and modulate gene expression in tissue-specific patterns determined by the peptide sequence. The published Bronchogen-specific evidence includes DNA-thermostability work — Bronchogen increased the DNA melting temperature of calf-thymus and mouse-liver DNA by 3.1 °C at narrow molar ratios — and lung-tissue gene-expression studies. The mechanism remains theoretical relative to the receptor-pharmacology standards used elsewhere in peptide research, and the in-vitro nuclear-translocation evidence is concentrated in publications from the Khavinson research network.
Research applications and the evidence base.
Published Bronchogen research is concentrated in Russian-language journals from the Khavinson group plus a small number of international collaborators. The studies span lung-tissue preclinical models, chronic-bronchitis research, and pulmonary-aging questions in rodent models. Independent replication outside the Khavinson research network is limited. There are no completed Western Phase III human clinical trials of Bronchogen, and the compound is not registered as a pharmaceutical in any major Western jurisdiction.
No human clinical trial has established administration parameters for Bronchogen; VialTalk does not provide community-sourced dosing.
Research context.
Bronchogen sits within the broader Khavinson-bioregulator family — Epitalon (pineal), Pinealon (CNS), Cortagen (cortex), Prostamax (prostate), and others. The compounds share discovery framework and mechanistic hypothesis but address different tissue systems. Researchers working in the Khavinson paradigm typically choose the compound matching their target tissue; Bronchogen is the lung-and-airway compound in that mapping.
Storage and handling.
Lyophilized Bronchogen should be kept refrigerated (2–8 °C) and protected from light. The peptide tolerates refrigerator-temperature storage reasonably well but does not tolerate repeated freeze-thaw cycles.
Quality and COA considerations.
A meaningful COA should confirm identity via mass spectrometry against the expected ~447 g/mol molecular weight, purity by HPLC (≥98% benchmark), and explicit identification by sequence (Ala-Asp-Glu-Leu) since several Khavinson bioregulators have similar short tetrapeptide sequences and labelling errors between them are a known quality issue in this market.
Research-use note: This monograph is an educational summary of the published research literature on Bronchogen. The compound has not been evaluated in completed Western human clinical trials and is not approved for human use in any major jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
